Inserm
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Apr 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Methods for Performing Antisense Oligonucleotide-Mediated Exon Skipping in the Retina of a Subject in Need Thereof (US 11,667,913) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 1 fee due Jun 30, 2027The maintenance fee for Selective Nox-1 inhibitor peptides and uses thereof (US 10,517,919) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for ANTI-CD277 Antibodies (US 11,904,004) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,932,808 | Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject In force · High confidence | In force | High confidence | |
| US 8,003,773 | Polynucleotides Encoding MHC Class I-Restricted Htert Epitopes, Analogues Thereof or Polyepitopes In force · High confidence | In force | High confidence | |
| US 9,867,971 | Device for Administering Cells and Cell-Therapy Methods Using Said Device In force · High confidence | In force | High confidence | |
| US 8,858,931 | Polynucleotides Encoding MHC Class I-Restricted Htert Epitopes, Analogues Thereof or Polyepitopes In force · High confidence | In force | High confidence | |
| US 11,667,913 | Methods for Performing Antisense Oligonucleotide-Mediated Exon Skipping in the Retina of a Subject in Need Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,150,989 | Fibrosis Susceptibility IL22RA2 Gene and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,188,695 | Calcineurin inhibitors for use in the treatment of lesional vestibular disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 11,904,004 | ANTI-CD277 Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 9,528,086 | Novel Recombinant Bordetella Strains In force · High confidence | In force | High confidence | |
| US 10,517,919 | Selective Nox-1 inhibitor peptides and uses thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 17: 6 patents in force now held by others · 36 lapsed for an unpaid fee · 28 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 23 abandoned · 20 no status recorded